What is MicroOptx?
MicroOptx is dedicated to the development and commercialization of platform technology designed to shunt aqueous humor to the surface of the eye. The company's primary objective is to create a safe and effective treatment for glaucoma by normalizing intraocular pressure, thereby halting the progression of blindness for a majority of patients. The company has projected European market approval for 2021 and U.S. and Canada market approval for 2022, indicating a significant push towards commercialization.
How much funding has MicroOptx raised?
MicroOptx has raised a total of $3.6M across 2 funding rounds:
Private Equity
$2.2M
Debt
$1.4M
Private Equity (2015): $2.2M, investors not publicly disclosed
Debt (2017): $1.4M, investors not publicly disclosed
What's next for MicroOptx?
With a major enterprise-level funding context and a recent strategic investment, MicroOptx is poised for significant growth and market penetration. The company's focus on achieving regulatory approvals in key global markets suggests an imminent transition from development to commercialization. This strategic financing will likely fuel market launch activities, sales force expansion, and further research and development to solidify its position in the competitive ophthalmic medical technology sector.
See full MicroOptx company page
